Identifying Patients with HR+ HER2- Early Breast Cancer who are at a Higher Risk of Recurrence
~20% of patients with HR+/HER2- EBC may progress to metastatic disease, commonly within a few years after primary treatment. This slide deck provides details on the clinical & pathological factors that may affect the risk of recurrence in people with EBC.
Date of Last Review: December 02, 2021
Are you satisfied with this content?